



March 19, 2026

Kissei Pharmaceutical Co., Ltd.  
(Code 4547, Tokyo Stock Exchange Prime Market)

## **Yselty® Tablets 100mg to Launch in Japan for Uterine Fibroids**

Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto, Nagano, Japan; Chairman and CEO: Mutsuo Kanzawa; "Kissei") announced that Yselty® tablets 100mg (generic name: Linzagolix choline), which was discovered and developed by Kissei for the treatment of uterine fibroids, has been launched in Japan on March 19, 2026.

Yselty® is an orally administered GnRH (gonadotropin-releasing hormone) antagonist. It acts by antagonizing GnRH at the GnRH receptor in the pituitary gland and consequently suppressing the secretion of gonadotropins. Ultimately, it reduces the production of estrogen in the ovaries and improves various symptoms of uterine fibroids.

In addition, we are also developing the drug in Japan for endometriosis.<sup>1</sup>

Overseas, Theramex (U.K.), to which we licensed out the technology, launched the product in Europe in September 2024 under the brand name Yselty® for the indication of uterine fibroids,<sup>2</sup> and in November of the same year obtained an additional indication for endometriosis from the European Medicines Agency (EMA).<sup>3</sup> In Taiwan, Synmosa Biopharma (Taiwan) is preparing for the launch. In South Korea and Canada, other companies, to which we have licensed out the technology, are developing Yselty®.

Uterine fibroids are reported to affect more than 70% of women.<sup>4</sup> They are particularly prevalent among women in their 30s and 40s, who are in the prime of their working lives, and can reduce patients' quality of life (QOL) through excessive menstrual periods and chronic pain symptoms, which also significantly affect their social activities. We have launched a disease awareness website, "be loving" (<https://www.kissei.co.jp/women/>), to improve access to medical care for those suffering from uterine fibroids and other female diseases.

Through the provision of new treatment options for uterine fibroids and disease awareness activities, we will contribute to the creation of a society in which women can thrive and play an active role.

There is no change to our consolidated financial results forecast for the fiscal year ending March 31, 2026.

1 News release: March 31, 2025

Kissei Initiates Phase III Clinical Trial for GnRH Antagonist "Linzagolix" Indicated for Endometriosis

2 News release: September 17, 2024

Launch of YSELTY® (generic name linzagolix) for uterine fibroid treatment in Europe

3 News release: December 23, 2024

Regarding the approval of the additional indication for endometriosis in Europe for the GnRH antagonist YSELTY® (generic name linzagolix)

4 Elizabeth A. Stewart, Shannon K. Laughlin-Tommaso, William H. Catherino, Sujata Lalitkumar, Devashana Gupta & Beverley Vollenhoven. Nature Reviews Disease Primers volume 2, Article number: 16043 (2016)

<https://www.nature.com/articles/nrdp201643>

<Reference>

Product Summary of Yselty® Tablets 100mg

Brand Name	Yselty® Tablets 100mg
Generic Name	Linzagolix choline
Indications	Improvement of the following symptoms based on uterine fibroids Excessive menstrual cycle, lower abdominal pain, back pain, anemia
Dosage and Administration	The usual adult dosage of Linzagolix is 200mg orally once daily. The first dose should be administered on days 1-5 of the menstrual cycle
Formulation	Film coated tablets
NHI drug price	Yselty® Tablets 100mg 429.10JPY
Manufacturing and Marketing Authorization Holder	Kissei Pharmaceutical Co., Ltd.
Date of Marketing Approval in Japan	December 22, 2025
Date of NHI drug price standard listing	March 18, 2026
Release Date	March 19, 2026

## Ysely® Tablets 100mg Photograph of Formulation



### About Uterine Fibroids

Uterine fibroids are benign tumors that develop in the smooth muscle that makes up the uterine myometrium and grow in a sex hormone-dependent manner. Typical symptoms are excessive menstruation and associated anemia, lower abdominal pain, and back pain.

According to the Ministry of Economy, Trade and Industry's estimate of economic loss due to women's health issues in 2024, the total annual loss of labor productivity due to menstrual complications is estimated at approximately 570 billion yen\*, and uterine fibroids are one of the causative diseases.

\*Ministry of Economy, Trade and Industry, "Estimation of Economic Losses Due to Women's Specific Health Issues and the Need for Health Management"

[https://www.meti.go.jp/policy/mono\\_info\\_service/healthcare/downloadfiles/jyosei\\_keizaisonshitsu.pdf](https://www.meti.go.jp/policy/mono_info_service/healthcare/downloadfiles/jyosei_keizaisonshitsu.pdf)

### About "be loving," a Website for Women's Diseases



It includes explanations of diseases to deepen understanding of health problems specific to women and a "Guide to First-time Gynecological Consultations" to increase the rate of gynecological consultations.

<https://www.kissei.co.jp/women/>